Lasmiditan analogues(Lasmiditan analogues) - 药物靶点：5-HT1F receptor_在研适应症：急性肾损伤_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

5-HT1F receptor

作用机制

5-HT1F receptor激动剂(5-羟色胺1F受体激动剂)

治疗领域

泌尿生殖系统疾病

在研适应症

急性肾损伤

非在研适应症-

原研机构

Mitohealth, Inc

在研机构

Mitohealth, Inc

非在研机构-

最高研发阶段临床阶段不明

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Lasmiditan analogues 相关的临床结果

登录后查看更多信息

100 项与 Lasmiditan analogues 相关的转化医学

登录后查看更多信息

100 项与 Lasmiditan analogues 相关的专利（医药）

登录后查看更多信息

1

项与 Lasmiditan analogues 相关的文献（医药）

2020-01-01·Headache: The Journal of Head and Face Pain2区 · 医学

The Headache Pipeline: Excitement and Uncertainty

2区 · 医学

Review

作者: McAllister, Peter ; Rapoport, Alan M.

There are many new treatment options available for migraine and more are coming. Three calcitonin gene‐related peptide (CGRP) antagonist monoclonal antibodies have been approved and a 4th is due in early 2020. Small molecule CGRP receptor‐blocking oral compounds, both for acute care and prevention, are also coming. Four neurostimulators are available, with others on the way. New acute treatments coming soon include the 5HT1Fagonist lasmiditan, a zolmitriptan intradermal micro‐needle patch, and a nasal mist sumatriptan with a permeability enhancer. Farther out, three novel dihydroergotamine delivery systems, and a liquid‐filled capsule of celecoxib show early promise. A new, safer form of methysergide is in the works, as is a longer‐duration onabotulinumtoxinA. As always with new products, questions regarding safety, tolerability, cost, and insurance coverage will need to be addressed. Despite these concerns and uncertainties, a robust headache treatment pipeline is good for patients who are not satisfied with the results of their treatment and/or cannot tolerate existing treatments.

100 项与 Lasmiditan analogues 相关的药物交易

登录后查看更多信息